Scripsamerica Inc · OTC:SCRCQ
Scripsamerica — Investor Presentation (November 2014)
31 slides from Scripsamerica's investor presentation, Nov 12, 2014
Slide 1: ScripsAmerica
Crys sBSitERICA
Slide 2: Safe Harbor Statement
This presentation may contain forward - looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not strictly historical s
Slide 3: ScripsAmerica - Leadership
Robert Schneiderman, CEO & Founding Partner » Numerous marketing and consulting projects, including projects that resulted in expanding client customer base via product development and placement into mass retail, as well as marketing program development. » Implemented marketing strategies, developed
Slide 4: Peter W. Megill, Corporate Controller
Peter W . Megill, Corporate Controller Pete is a CPA with over 25 years of experience in both private and public accounting . He has extensive experience in a broad range of industries, including pharmaceuticals, consumer products and manufacturing . He has over 15 years working for pharmaceuticals
Slide 5: ScripsAmerica, Inc. (OTCQB: SCRC)
Low - cost marketing, sales, and distribution capabilities of Rx and OTC drugs. Current and previous distribution networks include: U S Government Dept. of Defence Mass Merchants Supermarkets Chain Drug Stores Independent Drug Stores Hospitals Long Term Care HMO’s Home Health Care Clinics PBMs Stron
Slide 6: ScripsAmerica Today
» Market Cap $15.01M 156 Shareholders » 136,997,156 Shares Outstanding 250,000,000 Authorized 10 Shareholders Own 70Mil+ Shares » Preferred Convertible Debt $1.01M - Held by Board Member, Convertible into 5,996,211shares » Convertible Debt $ 800,000 » Other Debt $251,478, Unsecured, Non Convertible,
Slide 7: ScripsAmerica Historical & Outlook
Scrips America H istorical & O utlook T hrough 2 015 2010 2011 2012 2013 2014 est 2015 est SALES $3.2 M $5.9 M +84% $3.9 M* - 34% $7.6 M +95% $30.5 M +302% $63.3 M +108% INCOME BEFORE NON RECURRING CHARGES $487,022 $757,440 $270,838 ($667,129) $2.7 M $8.6 M +219% NET INCOME *Due to discontinuation o
Slide 8: Opportunities
O PPORTUNITIES MAIN AVENUE PHARMACY COMPOUNDING PHARMACY PARTNERSHIPS DISTRIBUTION FACILITY - PIMD INDEPENDENT PHARMACY SUPPLIER - WHOLESALE Rx DIABETES PATIENT DISTRIBUTION PHYSICIAN DISPENSING SUPPLY RAPIMED CHINA DISTRIBUTION – FORBES JOINT VENTURE
Slide 9: Main Avenue Pharmacy
Scrips Pharmacy produces its custom compounds for pain management therapy and scar treatment at its New Jersey pharmacy location. The New Jersey facility has the capability of handling hundreds of compounding prescriptions per month . We are currently DEA approved and licensed in 7 states for distri
Slide 10: Main Avenue Pharmacy - Compounding Benefits
Compounding Benefits: ▪ Non Addicting ▪ Effective for neuropathic pain. ▪ Non - steroidal anti - inflammatory. ▪ Produces a heating sensation that interferes with neurotransmitter. ▪ Stimulates circulation and causes a cool and soothing effect. ▪ Gel based for maximized absorption M ain A venue P ha
Slide 11: Benefits of topical compounds
▪ Direct delivery to site of pain, Oral medications affect the entire body. ▪ Low risk of dependency/abuse ▪ Customized treatment plans for patients with allergies or unique healthcare goals ▪ Proven solution as a replacement for oral medications in many instances ▪ Fewer side effects compared to or
Slide 12: Physician and systemic benefits
▪ Gives physicians an alternative treatment option and limits liability ▪ Minimal systemic effects, limiting damage to organ systems ▪ Decreased risk of drug - to - drug interactions
Slide 13: National survey and patient service
▪ National Survey: Topical Prescription Creams Reduce Pain in Five of Every Six Chronic Pain Patients, Without Need for Opioids or Other Narcotics ▪ See more at: http://globenewswire.com/news - release/2013/11/11/588697/10057195/en/National - Survey - Topical - Prescription - Creams - Reduce - Pain
Slide 14: Case Studies
C ase S tudies http://globenewswire.com/news - release/2013/11/11/588697/10057195/en/National - Survey - Topical - Prescription - Creams - Reduce - Pain - in - Five - of - Every - Six - Chronic - Pain - Patients - Without - Need - for - Opioids - or - Other - Narcotics.html http://www.ncbi.nlm.nih.g
Slide 15: Main Avenue Financials
Feb 12 thru June 30, 2014 est Q3 2014 est YTD Sept 30 th est Revenue 4,117,169 12,571,225 16,688,394 Cost Of Goods 423,584 1,094,272 1,157,856 Selling Expenses 3,134,029 9,310,994 12,445,023 Gross Profit 559,556 2,365,959 2,925,515 Total G&A 46,087 132,254 178,341 Interest Expense 8,296 33,668 41,96
Slide 16: Compounding Pharmacy Partnerships
ScripsAmerica has partnered with 4 additional pharmacies PIMD will distribute/supply raw materials to these pharmacies These additions will add 14 more states into which compounding prescriptions can be distributed The relationships require no additional capital investment by ScripsAmerica C ompound
Slide 17: ODT market growth projections
ODT market growth projections: 12 - 15% per year until 2015 The ODT market is one of the fastest growing sectors of the drug delivery market, with industry experts projecting a 12 - 15% annual growth rate for the next several years. Based on upward global growth trends of the past decade, the ODT ma
Slide 18: RapiMed Oral Delivery Technology
R APIMED O ral D elivery T echnology Rapid Release Fast Dissolving Tablets » High Profit Margins » Dissolves In Mouth In 25 - 35 Seconds » Fruit Flavors - Wild Cherry, Wild Grape » Faster Absorption Into System » Overcomes Objection To Taking Pills
Slide 19: RapiMed Oral Delivery Technology
» Children’s 2 - 11 Year Old Market Target » Highest Quality Ingredients » Over The Counter Product » Manufactured in the USA » Contract with Forbes for Distribution in China R APIMED O ral D elivery T echnology
Slide 20: RapiMed product image
‘in Your Child's Mouth © pias care ‘SEE NEW WARNINGS: INFORMATION iMed Junior Strength Pp. al n & For i ‘ages 6-11 Fever Relief ACETAMINOPHEN-160 mg each * Pain Reliever/Fever Reducer wy * Contains no Aspirin P * Melts in Your Child's Mouth 1 Na IN olmante de dolor y Reductor de bre No ontione beldo
Slide 21: Forbes and China/Hong Kong
Forbes, based in Shenzhen, China, will actively arrange a marketing and supply distribution operation of RapiMed(R) throughout China. It has already identified over 300 pharmacies and hospitals for potential distribution of RapiMed(R). ScripsAmerica and Forbes will coordinate to strategically develo
Slide 22: Oral Delivery Technology Beyond Current Product
O ral D elivery T echnology B eyond C urrent P roduct Other Formulations In Pipeline To Treat: » Vitamins » Sleep Deprivation » Allergies » Migraines
Slide 23: PIMD - Physician's Rx Supplier
PIMD International, LLC is a prescription drug and OTC branded products wholesaler located in Miami, FL. With a DEA license and state licenses to distribute into 11 states Medication wholesaler to various customers – pharmacies, hospitals, and physician offices. Service clients with medical supplies
Slide 24: WholesaleRx - Independent Pharmacy Supplier
Problem: Small chains and individual pharmacies unable to fill customer prescriptions when the Rx calls for controlled substances. To secure these substances the product manufacturers impose minimum order quantities far beyond the needs of the smaller operations. Solution: WholesaleRx – A DEA and St
Slide 25: WholesaleRx Continued
Scrips will order the goods from the manufacturers and ship them to Wholesale Rx, who will store and distribute controlled substances. Wholesale Rx will ship the products to the pharmacies in the same bottles received by the manufacturer – pick - n - pack operation. COD and credit card payment will
Slide 26: ScripsAmerica Financials
3 mos ending Sept 30 , 2014 est 3 mos ending Sept 30, 2013 9 mos ending Sept 30, 2014 est 9 mos ending Sept 30, 2013 Net Revenues 13,010,413 73,267 17,534,993 452,268 Cost of Goods 1,212,366 30,6001 1,816,048 424,485 Gross Profit 11,798,047 42,667 15,718,945 27,783 Total Operating Expenses 9,942,166
Slide 27: Balance Sheet
September 30, December 31, 2014 est 2013 ASSETS Current Assets Cash $ 1,200,099 $ 47,293 Accounts receivable trade, net of allowance of $317,025 2,788,220 - Receivable - contract packager, net of allowance of $108,422 and $408,150, respectively 1,120,231 1,088,598 Receivable - commissions WholeSaleR
Slide 28: Liabilities and Stockholders' Deficit
LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Line of credit $ - $ 99,222 Accounts payable and accrued expenses 2,475,221 226,570 Purchase order financing - related party 1,020,096 1,037,494 Term loans payable 407,379 - Term loan payable - related party 100,746 - Royalty payable 44,579 -
Slide 29: Commitments and Contingencies; Stockholders' Equity
Commitments and Contingencies Series A Convertible preferred stock - $.001 par value; 10,000,000 shares authorized, 2,990,252 issued and outstanding 1,043,000 # 1,043,000 Stockholders' Equity (Deficit) Common stock - $0.001 par value; 250,000,000 shares authorized; 136,166,625 and 91,792,839 shares
Slide 30: ScripsAmerica - Goals for Next 6 to 18 Months
» Expand the Compounding Rx Business - Add new Products and Formulations Launch RapiMeds in China ,U.S., Europe, Latin America, and Africa Uplist to Major Exchange Eliminate Convertible Notes Cash Flow Positive Other Formulations of the Oral Delivery Technology Strategic Acquisitions Manufacturing S
Slide 31: Contact Information
www.scripsamerica.com www.rapimeds.com Robert Schneiderman, CEO 800 - 957 - 7622 ext 101 bob@scripsamerica.com Jeffrey J. Andrews, CFO 800 - 957 - 7622 ext 102 Jeff@scripsamerica.com C ONTACT I NFORMATION
ScripsAmerica — Investor Presentation (November 2014) on 6ix